Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Goos

Showing results (681-690 of 716) with videos related to

Pageof 72
Sort By:
Neurobiology of Aging|August 13, 2014
7T T₂*-weighted magnetic resonance imaging reveals cortical phase differences between early- and late-onset Alzheimer's diseaseSanneke van Rooden, Nhat Trung Doan, Maarten J Versluis, et al.
Human Molecular Genetics|May 9, 2019
A de novo substitution in BCL11B leads to loss of interaction with transcriptional complexes and craniosynostosisJacqueline A C Goos, Walter K Vogel, Hana Mlcochova, et al.
Journal of Medicinal Chemistry|November 1, 2008
Indazole-based liver X receptor (LXR) modulators with maintained atherosclerotic lesion reduction activity but diminished stimulation of hepatic triglyceride synthesisJay Wrobel, Robert Steffan, S Marc Bowen, et al.
Oncotarget|October 27, 2015
A prognostic classifier for patients with colorectal cancer liver metastasis, based on AURKA, PTGS2 and MMP9Jeroen A C M Goos, Veerle M H Coupé, Mark A van de Wiel, et al.
Oncotarget|July 15, 2015
MGL ligand expression is correlated to BRAF mutation and associated with poor survival of stage III colon cancer patientsKristiaan Lenos, Jeroen A C M Goos, Ilona M Vuist, et al.
Human Mutation|May 10, 2016
Identification of Intragenic Exon Deletions and Duplication of TCF12 by Whole Genome or Targeted Sequencing as a Cause of TCF12-Related CraniosynostosisJacqueline A C Goos, Aimee L Fenwick, Sigrid M A Swagemakers, et al.
Journal of Medicinal Chemistry|August 6, 2004
Liver-selective glucocorticoid antagonists: a novel treatment for type 2 diabetesThomas W von Geldern, Noah Tu, Philip R Kym, et al.
British Journal of Cancer|November 18, 2016
Loss of KCNQ1 expression in stage II and stage III colon cancer is a strong prognostic factor for disease recurrenceSjoerd H den Uil, Veerle M H Coupé, Janneke F Linnekamp, et al.
American Journal of Human Genetics|September 5, 2015
Gain-of-Function Mutations in ZIC1 Are Associated with Coronal Craniosynostosis and Learning DisabilityStephen R F Twigg, Jennifer Forecki, Jacqueline A C Goos, et al.
The Journal of Pharmacology and Experimental Therapeutics|March 24, 2005
Hepatic glucocorticoid receptor antagonism is sufficient to reduce elevated hepatic glucose output and improve glucose control in animal models of type 2 diabetesPeer B Jacobson, Thomas W von Geldern, Lars Ohman, et al.
Pageof 72

Showing results (681-690 of 716) with videos related to

Sort By:
Pageof 72
Neurobiology of Aging|August 13, 2014
7T T₂*-weighted magnetic resonance imaging reveals cortical phase differences between early- and late-onset Alzheimer's diseaseSanneke van Rooden, Nhat Trung Doan, Maarten J Versluis, et al.
Human Molecular Genetics|May 9, 2019
A de novo substitution in BCL11B leads to loss of interaction with transcriptional complexes and craniosynostosisJacqueline A C Goos, Walter K Vogel, Hana Mlcochova, et al.
Journal of Medicinal Chemistry|November 1, 2008
Indazole-based liver X receptor (LXR) modulators with maintained atherosclerotic lesion reduction activity but diminished stimulation of hepatic triglyceride synthesisJay Wrobel, Robert Steffan, S Marc Bowen, et al.
Oncotarget|October 27, 2015
A prognostic classifier for patients with colorectal cancer liver metastasis, based on AURKA, PTGS2 and MMP9Jeroen A C M Goos, Veerle M H Coupé, Mark A van de Wiel, et al.
Oncotarget|July 15, 2015
MGL ligand expression is correlated to BRAF mutation and associated with poor survival of stage III colon cancer patientsKristiaan Lenos, Jeroen A C M Goos, Ilona M Vuist, et al.
Human Mutation|May 10, 2016
Identification of Intragenic Exon Deletions and Duplication of TCF12 by Whole Genome or Targeted Sequencing as a Cause of TCF12-Related CraniosynostosisJacqueline A C Goos, Aimee L Fenwick, Sigrid M A Swagemakers, et al.
Journal of Medicinal Chemistry|August 6, 2004
Liver-selective glucocorticoid antagonists: a novel treatment for type 2 diabetesThomas W von Geldern, Noah Tu, Philip R Kym, et al.
British Journal of Cancer|November 18, 2016
Loss of KCNQ1 expression in stage II and stage III colon cancer is a strong prognostic factor for disease recurrenceSjoerd H den Uil, Veerle M H Coupé, Janneke F Linnekamp, et al.
American Journal of Human Genetics|September 5, 2015
Gain-of-Function Mutations in ZIC1 Are Associated with Coronal Craniosynostosis and Learning DisabilityStephen R F Twigg, Jennifer Forecki, Jacqueline A C Goos, et al.
The Journal of Pharmacology and Experimental Therapeutics|March 24, 2005
Hepatic glucocorticoid receptor antagonism is sufficient to reduce elevated hepatic glucose output and improve glucose control in animal models of type 2 diabetesPeer B Jacobson, Thomas W von Geldern, Lars Ohman, et al.
Pageof 72